13F-HR: Regeneron Discloses Q3 2025 Equity Holdings

Regeneron Pharmaceuticals, Inc. filed its Form 13F-HR, revealing its equity investment portfolio totaling over $700 million as of September 30, 2025.

Summary

• Regeneron Pharmaceuticals, Inc. reported total equity holdings valued at $700,444,832 as of September 30, 2025.
• The portfolio consists of four common stock positions, all held with sole investment and voting discretion.
• Key holdings include Alnylam Pharmaceuticals, Inc. valued at $634,890,168 (1,392,303 shares), Intellia Therapeutics, Inc. valued at $63,950,724 (3,702,995 shares), Adverum Biotechnologies, Inc. valued at $819,518 (180,909 shares), and Adicet Bio, Inc. valued at $784,422 (968,183 shares).

Sentiment

Score: 5

Explanation: The filing is a routine regulatory disclosure of past equity holdings, providing factual information without expressing positive or negative sentiment regarding the reporting manager's operational performance or future prospects.

Positives

• The filing provides transparency regarding Regeneron's equity investment portfolio.
• Investments are concentrated in the biotechnology sector, aligning with Regeneron's core business and potential strategic interests.

Future Outlook

This Form 13F-HR provides a historical snapshot of equity holdings as of September 30, 2025, and does not contain any forward-looking statements or guidance regarding future investment strategies or performance.

Industry Context

Regeneron Pharmaceuticals, Inc., a major biopharmaceutical company, has disclosed investments primarily within the biotechnology sector. This indicates a focused investment strategy, potentially aligning with its core research and development interests or strategic partnerships within the industry.

Comparison to Industry Standards

• Institutional investment managers, particularly those with significant assets under management, routinely file Form 13F-HR reports to disclose their equity holdings, making this filing a standard regulatory compliance action.
• The concentration of investments in other biotechnology companies (Adicet Bio, Adverum Biotechnologies, Alnylam Pharmaceuticals, Intellia Therapeutics) is consistent with a strategic investor focusing on its core industry, similar to how other pharmaceutical or biotech giants might invest in emerging or complementary firms.

Stakeholder Impact

• Shareholders gain transparency into Regeneron's equity investment portfolio, offering insights into its strategic investment decisions and sector focus.

Key Dates

Keywords

Regeneron, 13F, Holdings, Equity, Investment, Portfolio, Biotechnology, Alnylam Pharmaceuticals, Intellia Therapeutics, Adverum Biotechnologies, Adicet Bio